search
Back to results

Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis (PRENATEX)

Primary Purpose

Fetal Malformation, Pregnancy Related, Rare Genetic Disease

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
CGH-array and exome sequencing
Sponsored by
University Hospital, Strasbourg, France
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Fetal Malformation focused on measuring Fetal malformations, Exome sequencing, antenatal cerebral malformations, antenatal ocular malformations, antenatal large hyperechoic kidneys

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Father and mother of an unborn child past the age of majority
  • Consent dated and signed by the mother and by the father
  • Father and mother able to understand the objectives and risks of the study
  • For the mother, pregnancy in progress (between 12 and 34 weeks)
  • For the mother, pregnancy with the presence of a malformation on ultrasound, confirmed by a doctor from the multidisciplinary diagnostic prenatal center, entering into the indications retained for this study
  • Clinical validation of the couple's eligibility by an expert for some of selected indications
  • Father and mother affiliated to a social protection health

Exclusion Criteria:

  • Identified genetic or chromosomal abnormality explaining the observed malformation
  • Inability to give informations to the father and / or mother (father or mother in emergency or life-threatening situation)
  • Father and / or mother under the protection of justice
  • Father and / or mother under guardianship or curatorship
  • Nursing woman

Sites / Locations

  • CHu de Besançon
  • CHU de Dijon
  • Hospices Civils de Lyon
  • Groupe Hospitalier Region Mulhouse Et Sud Alsace
  • CHU de Nancy
  • Hôpital d'Enfants Armand-Trousseau
  • Hôpital de la Pitié Salpêtrière
  • Hôpital Necker Enfants Malades
  • CHU de Reims
  • CHU de Rennes
  • Les Hôpitaux Universitaires de StrasbourgRecruiting
  • CHU de Toulouse

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)

Arm Description

Outcomes

Primary Outcome Measures

Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care
Comparison of the number of genetic diagnoses made by exome sequencing and by CGH-array.

Secondary Outcome Measures

Effects on pregnancy management and/or postnatal child care due to an etiological diagnosis
Percentage of antenatal and/or postnatal fetus/child care modified by the molecular result
Feasibility study of carrying out exome sequencing in the antenatal period in terms of time to deliver results
Time to results from the inclusion of the trio (in days) specifying the time for each step (reception, sequencing, bioinformatics analysis, interpretation) (in days)

Full Information

First Posted
May 26, 2020
Last Updated
November 10, 2020
Sponsor
University Hospital, Strasbourg, France
search

1. Study Identification

Unique Protocol Identification Number
NCT04406480
Brief Title
Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis
Acronym
PRENATEX
Official Title
Contribution of the Exome Sequencing in Antenatal Period Behind Ultrasound Features Suggestive of a Rare Genetic Disease
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
August 5, 2020 (Actual)
Primary Completion Date
September 2021 (Anticipated)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Congenital malformations concern 3% of pregnancies; most of them can be seen during pregnancy. For some malformations, an invasive sample (trophoblast biopsy or amniocentesis) is proposed to search a chromosomal abnormality by the technique of DNA chip. However, some strongly suggestive signs of a genetic (and not chromosomal) pathology have a very low diagnostic rate with this technique. In the absence of an etiological diagnosis, the prognosis for the unborn child is very difficult to assess, as we can't know if the fetal malformation is really isolated or associted to other unseen features as part of a syndromic condition. For some malformations strongly suggestive of a genetic condition, we propose to realize an exome (i.e. all coding parts of the genome) sequencing of the trio (child and the 2 parents) with a delivery time compatible with the emergency situation of a pregnancy (6 weeks maximum). We will apply bioinformatics filters to analyse only genes known to be involved in the malformation present in the unborn child and thus avoid the identification of variants in unrelated genes. These lists of genes have been previously validated by the Rare Disease Health Sectors and the affiliated diagnostic laboratories. The selected malformations are: 1) anomalies of the central nervous system (microcephaly (<- 2DS) with anomalies of gyration, anomalies of the posterior fossa, anomalies of the midline except agenesis of the corpus callosum), 2) ophthalmological anomalies (microphthalmia, hyperplasia vitreous) and 3) renal abnormalities (large hyperechoic kidneys).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fetal Malformation, Pregnancy Related, Rare Genetic Disease
Keywords
Fetal malformations, Exome sequencing, antenatal cerebral malformations, antenatal ocular malformations, antenatal large hyperechoic kidneys

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
90 trios (270 subjects: 90 fetus, 90 mothers, 90 fathers)
Arm Type
Other
Intervention Type
Genetic
Intervention Name(s)
CGH-array and exome sequencing
Intervention Description
A blood sample will be used for CGH-array and exome sequencing
Primary Outcome Measure Information:
Title
Diagnostic contribution of the exome sequencing in antenatal period in comparison with the chromosomal analysis (CGH-array) realized in current health care
Description
Comparison of the number of genetic diagnoses made by exome sequencing and by CGH-array.
Time Frame
13 months
Secondary Outcome Measure Information:
Title
Effects on pregnancy management and/or postnatal child care due to an etiological diagnosis
Description
Percentage of antenatal and/or postnatal fetus/child care modified by the molecular result
Time Frame
13 months
Title
Feasibility study of carrying out exome sequencing in the antenatal period in terms of time to deliver results
Description
Time to results from the inclusion of the trio (in days) specifying the time for each step (reception, sequencing, bioinformatics analysis, interpretation) (in days)
Time Frame
13 months
Other Pre-specified Outcome Measures:
Title
Difficulties of interpretation of the exome sequencing in antenatal period
Description
Numbers of variants of unknown signification identified by exome sequencing with and without bioinformatic filters (targeted exome)
Time Frame
13 months
Title
Identification of new genes responsible of fetal malformations
Description
If the results of CGH-array and targeted exome sequencing are negative, analysis of the entire exome sequencing to find new genes implicated in fetal development
Time Frame
13 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Father and mother of an unborn child past the age of majority Consent dated and signed by the mother and by the father Father and mother able to understand the objectives and risks of the study For the mother, pregnancy in progress (between 12 and 34 weeks) For the mother, pregnancy with the presence of a malformation on ultrasound, confirmed by a doctor from the multidisciplinary diagnostic prenatal center, entering into the indications retained for this study Clinical validation of the couple's eligibility by an expert for some of selected indications Father and mother affiliated to a social protection health Exclusion Criteria: Identified genetic or chromosomal abnormality explaining the observed malformation Inability to give informations to the father and / or mother (father or mother in emergency or life-threatening situation) Father and / or mother under the protection of justice Father and / or mother under guardianship or curatorship Nursing woman
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elise SCHAEFER
Phone
+33 3 88 12 81 20
Email
elise.schaefer@chru-strasbourg.fr
Facility Information:
Facility Name
CHu de Besançon
City
Besançon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lionel VAN MALDERGEM
Phone
+33 3 81 21 81 87
Email
lionel.van-maldergem@inserm.fr
First Name & Middle Initial & Last Name & Degree
Lionel VAN MALDERGEM
First Name & Middle Initial & Last Name & Degree
Juliette PIARD
First Name & Middle Initial & Last Name & Degree
Elise BOUCHER
Facility Name
CHU de Dijon
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christel THAUVIN
Phone
+33 3 80 29 53 13
Email
Christel.thauvin@chu-dijon.fr
First Name & Middle Initial & Last Name & Degree
Christel THAUVIN
First Name & Middle Initial & Last Name & Degree
Laurence FAIVRE
First Name & Middle Initial & Last Name & Degree
Arthur SORLIN
First Name & Middle Initial & Last Name & Degree
Sébastien MOUTTON
Facility Name
Hospices Civils de Lyon
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Audrey PUTOUX
Phone
+33 4 27 85 50 83
Email
Audrey.putoux@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Audrey PUTOUX
Facility Name
Groupe Hospitalier Region Mulhouse Et Sud Alsace
City
Mulhouse
ZIP/Postal Code
68070
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuelle GINGLINGER
Phone
+33 3 89 64 87 03
Email
GINGLINGERE@ghrmsa.fr
First Name & Middle Initial & Last Name & Degree
Emmanuelle GINGLINGER
First Name & Middle Initial & Last Name & Degree
Edgar MONTOYA RAMIREZ
Facility Name
CHU de Nancy
City
Nancy
ZIP/Postal Code
54042
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laetitia LAMBERT
Phone
+33 3 83 34 43 76
Email
l.lambert@chru-nancy.fr
First Name & Middle Initial & Last Name & Degree
Laetitia LAMBERT
First Name & Middle Initial & Last Name & Degree
Bruno LEHEUP
Facility Name
Hôpital d'Enfants Armand-Trousseau
City
Paris
ZIP/Postal Code
75012
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra AFENJAR
Phone
+33 1 44 73 61 86
Email
Alexandra.afenjar@aphp.fr
First Name & Middle Initial & Last Name & Degree
Alexandra AFENJAR
Facility Name
Hôpital de la Pitié Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Delphine HERON
Phone
+33 1 42 16 13 47
Email
Delphine.heron@aphp.fr
First Name & Middle Initial & Last Name & Degree
Delphine HERON
Facility Name
Hôpital Necker Enfants Malades
City
Paris
ZIP/Postal Code
75743
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tania ATTIE-BITACH
Phone
+33 1 44 49 51 44
Email
tania.attie@inserm.fr
First Name & Middle Initial & Last Name & Degree
Tania ATTIE-BITACH
Facility Name
CHU de Reims
City
Reims
ZIP/Postal Code
51092
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martine DOCO-FENZY
Phone
+33 3 26 78 90 03
Email
mdocofenzy@chu-reims.fr
First Name & Middle Initial & Last Name & Degree
Martine DOCO-FENZY
First Name & Middle Initial & Last Name & Degree
Céline POIRSIER
Facility Name
CHU de Rennes
City
Rennes
ZIP/Postal Code
35203
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sylvie ODENT
Phone
+33 2 99 26 67 44
Email
Sylvie.odent@chu-rennes.fr
First Name & Middle Initial & Last Name & Degree
Sylvie ODENT
Facility Name
Les Hôpitaux Universitaires de Strasbourg
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elise SCHAEFER
Phone
+33 3 88 12 81 20
Email
elise.schaefer@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Elise SCHAEFER
First Name & Middle Initial & Last Name & Degree
Hélène DOLLFUS
First Name & Middle Initial & Last Name & Degree
Salima EL CHEHADEH
First Name & Middle Initial & Last Name & Degree
Romain FAVRE
First Name & Middle Initial & Last Name & Degree
Vincent LAUGEL
Facility Name
CHU de Toulouse
City
Toulouse
ZIP/Postal Code
31059
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick CALVAS
Phone
+33 5 61 77 90 51
Email
calvas.p@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Patrick CALVAS

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Realization of Sequencing of All Known Human Genes in Case of Detection of Cerebral, Renal or Ophthalmological Fetal Malformations During Pregnancy in Order to Make an Etiological Diagnosis and to Precise the Fetal Prognosis

We'll reach out to this number within 24 hrs